利伐沙班单药治疗体重过轻/肥胖患者的心房颤动和冠状动脉疾病：需要证据。 - Suppr

Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed.

作者信息

Zhou Dao, Fan Jiaqi, Liu Xianbao

机构信息

Department of Cardiology, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

出版信息

JACC Asia. 2022 Dec 15;2(7):894-896. doi: 10.1016/j.jacasi.2022.09.008. eCollection 2022 Dec.

DOI:10.1016/j.jacasi.2022.09.008

PMID:36713757

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9877208/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ff0/9877208/dfd01258364a/fx1.jpg

相似文献

Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed.利伐沙班单药治疗体重过轻/肥胖患者的心房颤动和冠状动脉疾病：需要证据。

JACC Asia. 2022 Dec 15;2(7):894-896. doi: 10.1016/j.jacasi.2022.09.008. eCollection 2022 Dec.

Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories.利伐沙班单药治疗不同体重指数类别的心房颤动和稳定型冠状动脉疾病

JACC Asia. 2022 Aug 27;2(7):882-893. doi: 10.1016/j.jacasi.2022.08.004. eCollection 2022 Dec.

Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial.抗栓治疗用于既往动脉粥样硬化疾病患者的心房颤动和冠状动脉疾病：AFIRE 试验的事后分析。

J Am Heart Assoc. 2021 Nov 2;10(21):e020907. doi: 10.1161/JAHA.121.020907. Epub 2021 Oct 18.

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial.冠状动脉支架置入术后非瓣膜性心房颤动患者应用利伐沙班单药治疗：来自 AFIRE 试验的结果。

JACC Cardiovasc Interv. 2021 Nov 8;14(21):2330-2340. doi: 10.1016/j.jcin.2021.07.045.

Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.利伐沙班单药治疗与双联抗血小板治疗在伴有稳定型冠状动脉疾病的心房颤动患者中的全血栓栓塞和出血事件的比较：AFIRE 试验的事后二次分析。

JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561.

Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.心房颤动合并稳定性冠心病的抗栓治疗。

N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2.

Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.稳定型冠状动脉疾病患者应用利伐沙班发生心房颤动和缺血性事件（AFIRE）：一项多中心、前瞻性、随机、开放标签、平行分组研究方案。

Int J Cardiol. 2018 Aug 15;265:108-112. doi: 10.1016/j.ijcard.2018.04.131. Epub 2018 May 2.

Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis.利伐沙班单药治疗与联合治疗在房颤和稳定型冠心病患者的卒中与出血风险中的比较：AFIRE 试验亚组分析。

Am Heart J. 2021 Jun;236:59-68. doi: 10.1016/j.ahj.2021.02.021. Epub 2021 Feb 28.

Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.非瓣膜性心房颤动合并冠状动脉/外周动脉疾病成人患者抗凝治疗的有效性和安全性。

Am J Med. 2018 Sep;131(9):1075-1085.e4. doi: 10.1016/j.amjmed.2018.05.007. Epub 2018 May 26.

Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial.心房颤动合并稳定型冠状动脉疾病患者的出血事件及其对心血管事件和死亡的影响：来自 AFIRE 试验的观察。

Circ Cardiovasc Interv. 2021 Nov;14(11):e010476. doi: 10.1161/CIRCINTERVENTIONS.120.010476. Epub 2021 Sep 3.

引用本文的文献

Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy.冠心病介入治疗患者个性化抗血小板治疗的进展分析

Rev Cardiovasc Med. 2024 Dec 25;25(12):462. doi: 10.31083/j.rcm2512462. eCollection 2024 Dec.

本文引用的文献

JACC Asia. 2022 Aug 27;2(7):882-893. doi: 10.1016/j.jacasi.2022.08.004. eCollection 2022 Dec.

Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings.利伐沙班用于伴有稳定型冠状动脉疾病的心房颤动的剂量不足：AFIRE 试验结果。

Thromb Haemost. 2022 Sep;122(9):1584-1593. doi: 10.1055/s-0042-1744543. Epub 2022 Jun 13.

Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories.不同体重指数类别中房颤患者直接口服抗凝剂的治疗结局。

JACC Clin Electrophysiol. 2021 May;7(5):649-658. doi: 10.1016/j.jacep.2021.02.002. Epub 2021 Mar 31.

The impact of underweight and obesity on outcomes in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis on the obesity paradox.体重过轻和肥胖对接受抗凝治疗的心房颤动患者结局的影响：肥胖悖论的系统评价和荟萃分析。

Clin Cardiol. 2021 May;44(5):599-608. doi: 10.1002/clc.23593. Epub 2021 Mar 26.

Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis.直接口服抗凝剂在病态肥胖合并心房颤动患者中的疗效和安全性：系统评价和荟萃分析。

Eur Heart J Cardiovasc Pharmacother. 2022 Jun 8;8(4):325-335. doi: 10.1093/ehjcvp/pvab026.

Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation.亚洲房颤患者非维生素K拮抗剂口服抗凝药的超说明书用药剂量与临床结局

Heart Rhythm. 2020 Dec;17(12):2102-2110. doi: 10.1016/j.hrthm.2020.07.022. Epub 2020 Jul 20.

Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.心房颤动合并稳定性冠心病的抗栓治疗。

N Engl J Med. 2019 Sep 19;381(12):1103-1113. doi: 10.1056/NEJMoa1904143. Epub 2019 Sep 2.

Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Asians With Atrial Fibrillation: Meta-Analysis of Randomized Trials and Real-World Studies.非维生素 K 拮抗剂口服抗凝剂与华法林在亚洲房颤患者中的比较：随机试验和真实世界研究的荟萃分析。

Stroke. 2019 Oct;50(10):2819-2828. doi: 10.1161/STROKEAHA.119.026054. Epub 2019 Aug 19.

Aspirin on Top of Anticoagulation in Patients With Concomitant Stable Coronary Artery Disease and Atrial Fibrillation.在合并稳定型冠状动脉疾病和心房颤动的患者中，抗凝治疗基础上加用阿司匹林

Circulation. 2019 Jan 29;139(5):617-619. doi: 10.1161/CIRCULATIONAHA.118.037440.

Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation.亚洲人群心房颤动患者应用标准剂量及低剂量利伐沙班的有效性及安全性。

J Am Coll Cardiol. 2018 Jul 31;72(5):477-485. doi: 10.1016/j.jacc.2018.04.084.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献